• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

Regulatory T cell epitope content in human antibodies decreases during maturation

by Elena Iemma | Apr 21, 2025

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

by Elena Iemma | May 23, 2024

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

by Elena Iemma | May 23, 2024

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

by Elena Iemma | Sep 12, 2023

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

Poster: Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune-Cell Engagers

by Elena Iemma | May 1, 2023

Multi-Factored Immunogenicity Risk Assessment Approach for Bispecific Immune Cell-Engagers 
« Older Entries

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.